Novo Nordisk, the Danish pharmaceutical major behind popular weight-loss and diabetes drugs Wegovy and Ozempic, saw its market value drop by nearly $50 billion after it issued a weaker-than-expected outlook for 2026. The guidance raised concerns about slowing growth and led to a sharp sell-off in the company’s shares.
The company said it expects sales to fall between 5% and 13% in 2026, marking a significant slowdown after years of strong growth driven by global demand for obesity and diabetes treatments. The forecast came in well below market expectations and highlighted growing challenges in key markets, especially the United States.
Following the announcement, Novo Nordisk’s shares plunged about 16% on the Copenhagen exchange, while its US-listed stock fell more than 14%. The decline erased tens of billions of dollars in market capitalisation and marked one of the company’s steepest single-day losses in recent years.
Novo Nordisk attributed the weaker outlook mainly to pricing pressure in the US, where policy measures aimed at lowering drug costs are expected to impact revenues. The company is also facing intensifying competition, particularly from rival drugmaker Eli Lilly, which has gained momentum with its own obesity and diabetes medicines.
Another concern is the approaching patent expiries of some products in select international markets, which could open the door to cheaper alternatives and weigh on future sales. Together, these factors are expected to offset continued demand growth for GLP-1 drugs.
In its latest quarterly results, Novo Nordisk reported moderate performance. Sales of Wegovy rose by around 17% year-on-year, while Ozempic sales remained largely flat. Although the results broadly met expectations, investor focus remained firmly on the weaker forward guidance.
Company executives acknowledged that 2026 will be challenging but stressed confidence in the long-term outlook for obesity and diabetes care. Novo Nordisk said it will continue to invest in innovation, manage costs tightly and strengthen its product pipeline to protect growth over time.
Also Read: Washington Post in limelight after massive newsroom layoffs